Literature DB >> 27695332

The positive effects of high-frequency right dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation on memory, correlated with increases in brain metabolites detected by proton magnetic resonance spectroscopy in recently detoxified alcohol-dependent patients.

Jun Qiao1, Guixing Jin1, Licun Lei2, Lan Wang1, Yaqiang Du2, Xueyi Wang1.   

Abstract

OBJECTIVE: To explore the effect of right dorsolateral prefrontal cortex (DLPFC) repetitive transcranial magnetic stimulation (rTMS) on memory, and its correlation with levels of hippocampal brain metabolites detected by proton magnetic resonance spectroscopy (1H-MRS) in recently detoxified alcohol-dependent patients.
MATERIALS AND METHODS: In this randomized, double-blind sham-controlled trial, alcohol-dependent patients were enrolled and randomized into two groups: the experimental group (rTMS, 10 Hz, on right DLPFC, 20 sessions) and the control group (sham stimulation). Memory function was assessed using Hopkins Verbal Learning Test-Revised (HVLT-R) and Brief Visuospatial Memory Test-Revised (BVMT-R) before and after treatment. 1H-MRS was used to detect the levels of N-acetyl aspartic acid (NAA), choline (Cho), and creatine (Cr) in bilateral hippocampi before and after treatment.
RESULTS: Thirty-eight patients (18 in the experimental group and 20 in the control group) were included in the analyses. The experimental group showed significantly greater changes in HVLT-R, BVMT-R, NAA/Cr, and Cho/Cr after rTMS from baseline than the control group. The percentage change in BVMT-R and HVLT-R correlated with the percentage change in NAA/Cr and Cho/Cr in the right brain.
CONCLUSION: High-frequency right DLPFC rTMS was associated with improvement in memory dysfunction, which is correlated with levels of hippocampal brain metabolites detected by 1H-MRS in recently detoxified alcohol-dependent patients.

Entities:  

Keywords:  MR spectroscopy; alcohol dependence; memory; repetitive transcranial magnetic stimulation

Year:  2016        PMID: 27695332      PMCID: PMC5028171          DOI: 10.2147/NDT.S106266

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Long-term excessive alcohol use can lead to numerous neurological complications including damage to the cerebral cortex,1 and impaired cognitive2 and neuropsychological functioning.3 Although these effects may be partially reversed after alcohol use ceases,4 a treatment that can augment brain recovery during the early stage of alcohol abstinence would be beneficial. Repetitive transcranial magnetic stimulation (rTMS), a noninvasive neuromodulation technique, has been used as treatment for various neuropsychiatric disorders, including depression,5 obsessive–compulsive disorder,6 schizophrenia,7 and substance addiction.8 Modulation of the release of dopamine and glutamate in the mesolimbic dopaminergic system, a major pathway associated with substance-seeking behaviors, is a plausible mechanism underlying the effect of rTMS on addiction.9,10 The dorsolateral prefrontal cortex (DLPFC) has been shown to be associated with regulation of craving through the mesolimbic pathway.11 In randomized controlled trials, high-frequency rTMS over the right DLPFC was found to significantly reduce craving and stabilize cognitive performance in alcohol-dependent patients.12,13 DLPFC has also been shown to play a key role in memory function.14 Although studies have demonstrated that DLPFC rTMS is associated with enhancement of memory,15,16 few studies have evaluated the effect of DLPFC rTMS on memory in alcohol-dependent patients. We hypothesize that DLPFC rTMS could improve memory in alcohol-dependent patients who have recently undergone detoxification treatment. Changes in levels of brain metabolites often precede abnormalities in brain structure, and proton magnetic resonance spectroscopy (1H-MRS) is a recognized method for quantifying such changes. 1H-MRS has been used to evaluate hippocampal brain metabolites in various populations, including patients with mild cognitive impairment,17 patients with Alzheimer’s disease,18 cognitively normal older adults,19 and patients receiving whole brain radiotherapy.20 Results of these studies show hippocampal brain metabolites to be reliable preclinical markers of cognitive and memory function. In this clinical trial, we aimed to investigate the effect of high-frequency DLPFC rTMS on memory in recently detoxified alcohol-dependent patients and evaluate the relationship between the effect and changes in levels of hippocampal brain metabolites as detected by 1H-MRS.

Materials and methods

Subjects

This study was a single-center, randomized, double-blind, sham-controlled trial. Alcohol-dependent patients who were admitted to the Mental Health Institute of the First Hospital of Hebei Medical University from January 2011 to January 2012 were eligible for enrollment in this study. The inclusion criteria were as follows: 1) alcohol dependence in accordance with the diagnostic criteria of the International Classification of Diseases, 10th Revision, 2) Alcohol Dependence Scale score ≥14,21 3) Clinical Institute Withdrawal Assessment of Alcohol Revised Scale22 (CIWA-Ar) score <7, 4) right-handedness, and 5) ability to cooperate for cognitive function testing and magnetic resonance imaging (MRI). Patients were excluded if any of the following conditions were present: 1) Wernicke’s encephalopathy, 2) Korsakoff syndrome, 3) schizophrenia, 4) intellectual disability, 5) history of cranial trauma or severe neurological diseases, 6) dependence on psychoactive substances (excluding tobacco), and 7) contraindication to rTMS. All patients provided written informed consent, and the study was approved by the Institution Review Board of the First Hospital of Hebei Medical University. Patients were administered detoxification treatment consisting of oral diazepam 20–50 mg daily for 1–3 weeks. After the second week of alcohol detoxification, the patients were evaluated by two physicians and only those with a CIWA-Ar score <7 were enrolled and included in the analyses. A total of 40 patients were enrolled and randomized to the experimental group or the control group using a random number table; patients with odd numbers were allocated to the experimental group and those with even numbers to the control group.

Intervention

A Magstim RAPID2 stimulator (Magstim, Carmarthenshire, UK) equipped with a figure-8-shaped coil was used to deliver rTMS. Stimulation was administered over the right DLPFC. All patients received four treatment sessions. Duration of each treatment session was 5 days with a 2-day interval between sessions. During each session, patients received eight trains daily (10 Hz, 80% of resting motor threshold, 10 seconds on, 5 seconds off; 800 pulses). The control group was administered sham stimulation with the same parameters but with the coil placed perpendicular to the scalp.

Evaluation

Evaluations were performed by two physicians, and the results were reviewed by the senior chief physician. Evaluators and the patients were unaware of group assignment. Verbal and visuospatial episodic memory (immediate, delayed, and recognition for both) were assessed using the Hopkins Verbal Learning Test-Revised (HVLT-R)23 and Brief Visuospatial Memory Test-Revised (BVMT-R),24 respectively. 1H-MRS was used to detect bilateral hippocampal brain metabolites. HVLT-R is a tool used to assess verbal learning and memory that requires recall of a list of 12 words (from three semantic categories) over three learning trials, free recall after a delay, and a recognition trial. BVMT-R is a common assessment for visual learning that requires patients to reproduce six figures at the correct location after a 10-second presentation. Each figure is scored a maximum of two points (one point for correct form, one point for correct location), and the total score over three trials is calculated. For measurement of brain metabolites, MRI was performed on a GE Signa TwinSpeed 1.5T MRI (GE Healthcare, Buckinghamshire, UK), using three-dimensional spoiled gradient echo. Hippocampal volume was measured using coronal and sagittal planes. Point-resolved echo spin spectroscopy was utilized to collect single-voxel magnetic resonance spectra from the left and right sides. Shimming and water inhibition were automatically completed by the scanner, with a water suppression rate >98%. Scanning was performed with the following parameters: repetition time =1,500 ms, echo time =35 ms, number of acquisitions =128, voxel size =20×20×20 mm, and acquisition time =3 minutes 48 seconds for each site. 1H-MRS was applied on bilateral hippocampi to detect N-acetyl aspartic acid (NAA), choline (Cho), and creatine (Cr). Image processing was performed at a workstation using vendor-provided software (GE-Funtool; GE Healthcare Bio-Sciences Corp.) to measure the levels of NAA, Cho, and Cr. As the Cr concentration remains relatively constant, its concentration was used as an internal reference for calculating the metabolite ratio (NAA/Cr and Cho/Cr).25

Statistical analysis

Continuous variables are presented as median with inter-quartile range, and categorical variables are presented as count with percentage. To compare the characteristics and outcomes between the two groups, Mann–Whitney U-test and chi-square tests were used for continuous and categorical variables, respectively. Cohen’s d was calculated to compare the changes in HVLT-R and BVMT-R scores between the groups. Correlation between the percentage changes in memory function and measures of brain metabolites was tested by Spearman’s rank correlation coefficient. A two-tailed P<0.05 indicated statistical significance. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 19.0 (IBM Corporation, Armonk, NY, USA).

Results

A total of 40 patients were enrolled in this study. Two patients in the experimental group were excluded due to being lost to follow-up; therefore, data from 18 patients in the experimental group and 20 patients in the control group were included in the analyses. There was no significant difference between the experimental and the control groups regarding median age (49 years vs 48 years, P=0.536), sex (male percentage: 66.7% vs 65.0%, P=0.914), or median duration of alcohol use (21.0 years vs 18.5 years, P=0.438). Change in memory function after rTMS is presented in Figure 1. Both groups showed improvement in HVLT-R and BVMT-R scores from baseline. Improvement was significantly greater in the experimental group than the control group for both HVLT-R (change: 3.1 vs 1.7, P=0.003, Cohen’s d=1.15) and BVMT-R (change: 6.0 vs 1.2, P<0.001, Cohen’s d=3.56).
Figure 1

Change in memory function assessed by HVLT-R and BVMT-R after high-frequency right dorsolateral prefrontal cortex rTMS in recently detoxified alcohol-dependent patients.

Notes: Both groups showed improved memory after rTMS from baseline. The experimental group had significantly greater improvement than the control group in HVLT-R (*P=0.003, Cohen’s d=1.15) and BVMT-R (**P<0.001, Cohen’s d=3.56) scores.

Abbreviations: rTMS, repetitive transcranial magnetic stimulation; HVLT-R, Hopkins Verbal Learning Test-Revised; BVMT-R, Brief Visuospatial Memory Test-Revised.

Regarding changes in measurements of hippocampal brain metabolites, both groups exhibited bilateral increases in NAA/Cr and Cho/Cr after rTMS from baseline. The experimental group had significantly greater percentage change from baseline than the control group in NAA/Cr (left: 16.3% vs 5.7%, P=0.023; right: 28.7% vs 6.5%, P=0.001) and Cho/Cr (left: 26.7% vs 6.1%, P=0.005; right: 29.3% vs 6.8%, P<0.001; Table 1).
Table 1

The changes of brain metabolites after treatment

VariablesExperimental group (n=18)Control group (n=20)P-value
Left brain
NAA
 Pretreatment55 (51–61)50 (46–56)0.032
 Posttreatment57 (49–62)52 (49–55)0.065
 Change3 (−3 to 6)2 (−1 to 3)0.527
 Change (%)5.5 (−5.8 to 9.7)3.8 (−1.9 to 6.8)0.804
Cho
 Pretreatment52 (42–55)47 (44–51)0.285
 Posttreatment54 (50–63)49 (44–53)0.005
 Change7 (3–12)2 (−3 to 4)0.004
 Change (%)12.5 (5.5–25.9)3.3 (−5.7 to 8.0)0.004
Cr
 Pretreatment45 (43–48)43 (41–46)0.090
 Posttreatment41 (39–43)43 (39–44)0.371
 Change−5 (−6 to −1)−3 (−3 to 1)0.017
 Change (%)−8.8 (−13.9 to −2.4)−5.3 (−7.5 to 1.2)0.021
NAA/Cr
 Pretreatment1.2 (1.2–1.3)1.2 (1.1–1.3)0.292
 Posttreatment1.4 (1.1–1.6)1.3 (1.2–1.3)0.077
 Change0.2 (0.1–0.3)0.1 (0–0.1)0.017
 Change (%)16.3 (8.3–26.7)5.7 (1.4–12.1)0.023
Cho/Cr
 Pretreatment1.1 (0.9–1.3)1.1 (1.0–1.1)0.930
 Posttreatment1.4 (1.2–1.5)1.1 (1.1–1.2)0.001
 Change0.3 (0.1–0.4)0.1 (0–0.1)0.003
 Change (%)26.7 (4.6–40.6)6.1 (−1.4 to 12.8)0.005
Right brain
NAA
 Pretreatment54 (49–56)52 (47–55)0.333
 Posttreatment60 (57–65)54 (47–58)0.000
 Change7 (4–13)3 (−2 to 4)0.001
 Change (%)11.8 (7.8–27.7)4.5 (−3.2 to 8.3)0.002
Cho
 Pretreatment49 (42–52)49 (42–53)0.736
 Posttreatment58 (53–64)48 (46–55)0.004
 Change10 (6–13)4 (1.0 to 6)0.001
 Change (%)22.9 (9.5–30.8)7.8 (0.7–13.0)0.003
Cr
 Pretreatment46 (43–49)45 (42–48)0.340
 Posttreatment43 (40–45)44 (43–46)0.268
 Change−4 (−6 to 1)0 (−3 to 2)0.077
 Change (%)−8.7 (−10.7 to 2.4)−1.1 (−6.6 to 3.3)0.047
NAA/Cr
 Pretreatment1.2 (1.0–1.2)1.1 (1.0–1.2)0.988
 Posttreatment1.4 (1.2–1.6)1.2 (1.1–1.3)0.002
 Change0.3 (0.1–0.4)0.1 (0–0.1)0.001
 Change (%)28.7 (6.4–40.1)6.5 (−1.5 to 10.1)0.001
Cho/Cr
 Pretreatment1.0 (1.0–1.1)1.1 (0.9–1.2)0.599
 Posttreatment1.4 (1.2–1.5)1.1 (1.0–1.2)0.001
 Change0.3 (0.2–0.5)0.1 (0–0.2)<0.001
 Change (%)29.3 (14.6–45.6)6.8 (−0.2 to 14.5)<0.001

Note: Data are presented as median (interquartile range).

Abbreviations: NAA, N-acetyl aspartic acid; Cho, choline compound; Cr, creatine compound.

Correlations between the percentage change in memory function and the percentage change in brain metabolites are presented in Table 2. In the left brain, the percentage change in BVMT-R significantly and positively correlated with the percentage change in NAA/Cr (r=0.324) and Cho/Cr (r=0.340). No significant correlation between HVLT-R and brain metabolites was noted in the left brain. In the right brain, the percentage change in both HVLT-R and BVMT-R showed significant positive correlation with the percentage change in both NAA/Cr and Cho/Cr (Table 2).
Table 2

Correlations between the percentage changes of memory function and the percentage change of brain metabolites by Spearman’s rank correlation coefficient

VariablesHVLT-RBVMT-R
Left brain
 NAA0.0450.138
 Cho−0.0270.354*
 Cr−0.127−0.254
 NAA/Cr0.2740.324*
 Cho/Cr0.0620.340*
Right brain
 NAA0.345*0.561*
 Cho0.2540.352*
 Cr−0.311−0.352*
 NAA/Cr0.392*0.532*
 Cho/Cr0.405*0.461*

Note:

P<0.05.

Abbreviations: HVLT-R, Hopkins Verbal Learning Test-Revised; BVMT-R, Brief Visuospatial Memory Test-Revised; NAA, N-acetyl aspartic acid; Cho, choline compound; Cr, creatine compound.

No major adverse events were reported. Minor adverse events were reported in eight patients: five patients complained of headache (three in experimental group and two in control group) and three patients experienced dizziness (two in experimental group and one in control group). All adverse events resolved spontaneously.

Discussion

In this study, treatment with high-frequency DLPFC rTMS was associated with improved memory in recently detoxified alcohol-dependent patients. Furthermore, improvement in memory positively correlated with increase in levels of brain metabolites, an indication of brain recovery. To the best of our knowledge, this is the first study to assess the effect of high-frequency DLPFC rTMS on memory and evaluate the correlation between the effect on memory and change in levels of hippocampal brain metabolites in this population. The effects of DLPFC rTMS on craving reduction, mood modulation, and cognitive improvement in alcohol-dependent patients have been investigated in several studies. Mishra et al reported a significant reduction in alcohol craving in alcohol-detoxified patients following ten sessions of 10 Hz right DLPFC rTMS.12 In a follow-up study, the authors found similar significant reductions in craving when rTMS was administered over either the right or left DLPFC.26 Herremans et al found no effect on craving after one session of 20 Hz right DLPFC rTMS in detoxified alcohol-dependent patients. The author commented that the lack of effect may have resulted from inadequate stimulation.27 In a subsequent study, however, the authors found that a single session of 20 Hz right DLPFC rTMS was sufficient to significantly increase the stability of cognitive performance even without a reduction in craving.13 Furthermore, a study by Girardi et al reported significant reductions in both craving and depressive symptoms with 20 sessions of 20 Hz bilateral DLPFC rTMS as adjunctive therapy to standard drug treatment in concurrent alcohol-dependent patients with dysthymic disorder.28 In a study of bilateral DLPFC rTMS in patients with major depressive disorder with or without alcohol dependence, significant improvement in depressive symptoms was noted regardless of alcohol dependence.29 In our study, right DLPFC rTMS was associated with significant improvement in memory as assessed by HVLT-R and BVMT-R. The results provide further evidence for DLPFC rTMS as a potential treatment for improving memory and stabilizing cognitive performance in this population. In this study, change in levels of bilateral hippocampal NAA, Cho, and Cr after DLPFC rTMS was evaluated using 1H-MRS. Previous studies have shown that hippocampal brain metabolites are useful preclinical predictors for cognitive decline and memory dysfunction.19 In a cross-sectional study, lower values of left hippocampal NAA/Cr were found to be significantly associated with poorer verbal learning (r=0.44) and memory retention (r=0.41) in older people suffering from long-term depression.30 In a prospective study, a significant decrease in hippocampal NAA level was noted after whole brain radiation, and left hippocampal NAA level was found to correlate with declined memory after radiotherapy.20 In the current study, degree of improvement in memory after high-frequency DLPFC rTMS was positively and significantly correlated with increase in hippocampal NAA/Cr and Cho/Cr. The results strongly support the positive effect of DLPFC rTMS on memory recovery in recently detoxified alcohol-dependent patients. There were several limitations in this study. First is the limited number of patients enrolled in this study. Second, we did not control for some potential confounding factors, including body mass index, education level, and tobacco dependence. Third, as most participants reported that their drinking habits varied over time, amount of alcohol use could not be precisely assessed. Additionally, duration of alcohol use was self-reported, and recall bias is an inherent limitation of self-reported data. Finally, we did not evaluate craving; therefore, we could not evaluate the relationship between improvement in memory and learning and improvement in alcohol dependence.

Conclusion

High-frequency DLPFC rTMS was associated with improvement in memory in recently detoxified alcohol-dependent patients, and the improvement was positively correlated with increase in levels of hippocampal brain metabolites. Further investigations in a greater number of patients are necessary to better explore the anticraving and memory-improving effects of this potentially beneficial treatment.
  28 in total

1.  Altered cortical excitability in obsessive-compulsive disorder.

Authors:  B D Greenberg; U Ziemann; G Corá-Locatelli; A Harmon; D L Murphy; J C Keel; E M Wassermann
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

2.  Temporal dynamics and determinants of whole brain tissue volume changes during recovery from alcohol dependence.

Authors:  Stefan Gazdzinski; Timothy C Durazzo; Dieter J Meyerhoff
Journal:  Drug Alcohol Depend       Date:  2005-01-15       Impact factor: 4.492

3.  Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease.

Authors:  Nibal Ackl; Marcus Ising; Yvonne A Schreiber; Monika Atiya; Annette Sonntag; Dorothee P Auer
Journal:  Neurosci Lett       Date:  2005 Aug 12-19       Impact factor: 3.046

4.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

Authors:  J T Sullivan; K Sykora; J Schneiderman; C A Naranjo; E M Sellers
Journal:  Br J Addict       Date:  1989-11

5.  Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: a comparison with standard treatment.

Authors:  Paolo Girardi; Chiara Rapinesi; Flavia Chiarotti; Georgios D Kotzalidis; Daria Piacentino; Daniele Serata; Antonio Del Casale; Paola Scatena; Flavia Mascioli; Ruggero N Raccah; Roberto Brugnoli; Vittorio Digiacomantonio; Vittoria Rachele Ferri; Stefano Ferracuti; Abraham Zangen; Gloria Angeletti
Journal:  World J Biol Psychiatry       Date:  2014-08-20       Impact factor: 4.132

6.  Sequential MR imaging and proton MR spectroscopy in patients who underwent recent detoxification for chronic alcoholism: correlation with clinical and neuropsychological data.

Authors:  M Bendszus; H G Weijers; G Wiesbeck; M Warmuth-Metz; A J Bartsch; S Engels; J Böning; L Solymosi
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

7.  Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study.

Authors:  N Schuff; D Amend; F Ezekiel; S K Steinman; J Tanabe; D Norman; W Jagust; J H Kramer; J A Mastrianni; G Fein; M W Weiner
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

8.  Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study.

Authors:  N R Jagannathan; N G Desai; P Raghunathan
Journal:  Magn Reson Imaging       Date:  1996       Impact factor: 2.546

9.  Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study.

Authors:  Biswa R Mishra; S Haque Nizamie; Basudeb Das; Samir K Praharaj
Journal:  Addiction       Date:  2010-01       Impact factor: 6.526

Review 10.  Brain stimulation in the study and treatment of addiction.

Authors:  Jodie Feil; Abraham Zangen
Journal:  Neurosci Biobehav Rev       Date:  2009-11-13       Impact factor: 8.989

View more
  8 in total

1.  Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead.

Authors:  Hamed Ekhtiari; Hosna Tavakoli; Giovanni Addolorato; Chris Baeken; Antonello Bonci; Salvatore Campanella; Luis Castelo-Branco; Gaëlle Challet-Bouju; Vincent P Clark; Eric Claus; Pinhas N Dannon; Alessandra Del Felice; Tess den Uyl; Marco Diana; Massimo di Giannantonio; John R Fedota; Paul Fitzgerald; Luigi Gallimberti; Marie Grall-Bronnec; Sarah C Herremans; Martin J Herrmann; Asif Jamil; Eman Khedr; Christos Kouimtsidis; Karolina Kozak; Evgeny Krupitsky; Claus Lamm; William V Lechner; Graziella Madeo; Nastaran Malmir; Giovanni Martinotti; William M McDonald; Chiara Montemitro; Ester M Nakamura-Palacios; Mohammad Nasehi; Xavier Noël; Masoud Nosratabadi; Martin Paulus; Mauro Pettorruso; Basant Pradhan; Samir K Praharaj; Haley Rafferty; Gregory Sahlem; Betty Jo Salmeron; Anne Sauvaget; Renée S Schluter; Carmen Sergiou; Alireza Shahbabaie; Christine Sheffer; Primavera A Spagnolo; Vaughn R Steele; Ti-Fei Yuan; Josanne D M van Dongen; Vincent Van Waes; Ganesan Venkatasubramanian; Antonio Verdejo-García; Ilse Verveer; Justine W Welsh; Michael J Wesley; Katie Witkiewitz; Fatemeh Yavari; Mohammad-Reza Zarrindast; Laurie Zawertailo; Xiaochu Zhang; Yoon-Hee Cha; Tony P George; Flavio Frohlich; Anna E Goudriaan; Shirley Fecteau; Stacey B Daughters; Elliot A Stein; Felipe Fregni; Michael A Nitsche; Abraham Zangen; Marom Bikson; Colleen A Hanlon
Journal:  Neurosci Biobehav Rev       Date:  2019-07-02       Impact factor: 8.989

Review 2.  Targeting the Salience Network: A Mini-Review on a Novel Neuromodulation Approach for Treating Alcohol Use Disorder.

Authors:  Claudia B Padula; Lea-Tereza Tenekedjieva; Daniel M McCalley; Hanaa Al-Dasouqi; Colleen A Hanlon; Leanne M Williams; F Andrew Kozel; Brian Knutson; Timothy C Durazzo; Jerome A Yesavage; Michelle R Madore
Journal:  Front Psychiatry       Date:  2022-05-17       Impact factor: 5.435

3.  Effects of neuromodulation on cognitive performance in individuals exhibiting addictive behaviors: A systematic review.

Authors:  Katherine R Naish; Lana Vedelago; James MacKillop; Michael Amlung
Journal:  Drug Alcohol Depend       Date:  2018-10-03       Impact factor: 4.492

4.  Effects of Repetitive Transcranial Magnetic Stimulation on Cognitive Function in Patients With Stress-Related Depression: A Randomized Double-Blind fMRI and 1H-MRS Study.

Authors:  Yuxin Chen; Xiuzhen Li; Lubin Wang; Shushi Tian; Yuanwang Chen; Feng Wang; Kesheng Gu; Ying Wang; Guangkai Xu; Shangrong Zhang; Jie Liu; Haipeng Wang; Zongxin Jia; Liqing Li; Xiaohui Wang; Fang Xie; Xue Wang; Shida Wang; Cong Xue; Yun Zhao; Lingjia Qian
Journal:  Front Neurol       Date:  2022-04-15       Impact factor: 4.086

Review 5.  A comprehensive review of transcranial magnetic stimulation in secondary dementia.

Authors:  Giuseppe Lanza; Francesco Fisicaro; Raffaele Dubbioso; Federico Ranieri; Andrei V Chistyakov; Mariagiovanna Cantone; Manuela Pennisi; Alfio Antonio Grasso; Rita Bella; Vincenzo Di Lazzaro
Journal:  Front Aging Neurosci       Date:  2022-09-26       Impact factor: 5.702

6.  White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients.

Authors:  Mahsa Dadar; Yashar Zeighami; Yvonne Yau; Seyed-Mohammad Fereshtehnejad; Josefina Maranzano; Ronald B Postuma; Alain Dagher; D Louis Collins
Journal:  Neuroimage Clin       Date:  2018-09-27       Impact factor: 4.881

7.  Effects of Non-invasive Neuromodulation on Executive and Other Cognitive Functions in Addictive Disorders: A Systematic Review.

Authors:  Renée S Schluter; Joost G Daams; Ruth J van Holst; Anna E Goudriaan
Journal:  Front Neurosci       Date:  2018-09-19       Impact factor: 4.677

8.  Influence of Repetitive Transcranial Magnetic Stimulation on Human Neurochemistry and Functional Connectivity: A Pilot MRI/MRS Study at 7 T.

Authors:  Heidi Gröhn; Bernadette T Gillick; Ivan Tkáč; Petr Bednařík; Daniele Mascali; Dinesh K Deelchand; Shalom Michaeli; Gregg D Meekins; Michael J Leffler-McCabe; Colum D MacKinnon; Lynn E Eberly; Silvia Mangia
Journal:  Front Neurosci       Date:  2019-11-27       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.